What Adenocyte does

Adenocyte Ltd. is a privately held Israeli medical technology company founded in 2018 and headquartered in Jerusalem, with research laboratories in Haifa, focused on the early detection of pancreatic adenocarcinoma and its precancerous precursors. The company's core product is LINFU (Low Intensity Non-Focused Ultrasound), a patented and FDA-cleared ultrasound waveform delivered extracorporeally for approximately 15 minutes during a standard upper endoscopy. LINFU leverages the capillary-bed vibration induced by FDA-approved microbubble contrast agents to loosen intercellular bonds in glandular epithelium, increasing the natural exfoliation rate of pancreatic ductal cells by more than 100-fold and converting previously inadequate pancreatic juice cytology samples into specimens suitable for cytopathological analysis.

The technology is positioned as a population-level screening analog to the Pap smear for cervical cancer, marketed under the tagline 'The Pap Smear for the Pancreas.' Adenocyte operates a B2B / hospital-based distribution model in which care coordination staff route high-risk patients (first-degree relatives of pancreatic cancer victims and carriers of one of 11 genetic markers) through a network of designated screening centers in the United States (New York City, Southern California, Sarasota/Ft Myers, South Florida, Orlando) and Jerusalem. The company's principal investigator site is Sarasota Memorial Hospital, and key opinion leader partnerships include NYU Langone Health and Lee Health, with academic R&D rooted at the Technion – Israel Institute of Technology and GE Healthcare having developed the underlying FDA-cleared ultrasound hardware.

Commercialization is at an early stage. Adenocyte launched a nationwide clinical registry study for elevated-risk patients in February 2024 with a second registry for average-risk patients expected in 2025, funded in part by a $10 million round led by iGan Partners. The company has not publicly disclosed pricing or reimbursement arrangements, and no revenue figures are available; near-term revenue mechanics are expected to flow through hospital facility fees and partnership contracts with health systems rather than direct-to-consumer sales. The management team combines academic, clinical, and commercial leadership drawn from the Technion, Sarasota-based GI oncology, and prior medical device commercialization experience.

Name

Adenocyte

Legal name

Adenocyte Ltd.

Website

https://adenocyte.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Adenocyte is an Israeli medical technology company that markets LINFU, an FDA-cleared ultrasound waveform that enhances pancreatic juice cytology for early detection of pancreatic cancer in high-risk patients via partner hospital screening centers.

Ownership category

akta.pro rank

Product category

Cancer Screening Technology

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Diagnostic Imaging Centers (621512)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN)

akta.pro secondary industries

Advanced Endoscopy (ERCP/EUS/Interventional) (HLAKAEAC), Pancreaticobiliary Disorders (HLAKAEAG), Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG)

Keywords

• Pancreatic cancer screening
• Ultrasound cytology technology
• Epithelial cell exfoliation
• Cytopathology enhancement
• Medical diagnostic devices

Headquarters

HQ city

Jerusalem

HQ country

Israel

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Go-to-market motion3 records

Distribution channels8 records

Marketing channels8 records

Core offering

Adenocyte develops and commercializes LINFU® (Low Intensity Non-Focused Ultrasound), a patented, FDA-cleared ultrasound waveform technology applied extracorporeally for approximately 15 minutes during a standard upper endoscopy to dramatically increase natural epithelial cell exfoliation using FDA-approved microbubble contrast agents. The primary clinical application enriches pancreatic juice cytopathology specimens to enable screening of high-risk asymptomatic patients for pancreatic intraepithelial neoplasia (PanIn-2, PanIn-3) and early pancreatic ductal adenocarcinoma (PDAC), with additional potential applications in prostate, breast, and liquid biopsy reflex cytology.

Product overview

Adenocyte is a medical technology company founded in 2018, focused on developing and commercializing LINFU® (Low Intensity Non-Focused Ultrasound), its patented, FDA cleared ultrasound waveform technology. LINFU® is the core product platform that works in conjunction with standard upper endoscopy procedures to enhance the collection of epithelial cells for cytopathological analysis. The technology increases the natural rate of cell exfoliation by utilizing ultrasound microbubble contrast agents to loosen intercellular bonds in glandular epithelium. The company positions this capability under 'The Pap Smear for the Pancreas™' branding, applying the proven screening principle of cervical cancer detection to pancreatic cancer screening for high-risk patients.

Differentiator

Problem solved

Functional benefit

Brands

• LINFU®: Low Intensity Non-Focused Ultrasound technology platform designed to enhance epithelial cell exfoliation for dysplasia and cancer screening.

Products and services

• LINFU® (Low Intensity Non-Focused Ultrasound) A brief, extracorporeal application of a specially designed, FDA-cleared, low-intensity, non-focused ultrasound beam that significantly increases the natural rate of epithelial cell exfoliation into surrounding body fluid, enhancing cytological specimens used to screen for dysplasia and cancer. The first clinical application enriches pancreatic juice cytopathology specimens to screen high-risk asymptomatic patients for pancreatic intraepithelial neoplasia (PanIn-2 and PanIn-3) and early pancreatic ductal adenocarcinoma (PDAC). The procedure is performed during a standard upper endoscopy for approximately 15 minutes.

Named customers3 records

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Six partnerships are on record, tiered core, major and supporting.

• Technion – Israel Institute of TechnologycoreStrategic or Co-development PartnerAdenocyte's laboratories are located in Haifa and Jerusalem, with clinical development and testing performed at the Technion – Israel Institute of Technology Medical Center. Successful preclinical trials in a porcine model were conducted at Technion from 2018–2021. The Technion is central to the company's R&D and represents its primary academic and clinical research collaboration. Dr. Dan Adam, CTO, is a full Professor at the Technion's Dept. of Biomedical Engineering and served as Dean from 2009–2012.
• Sarasota Memorial HospitalcoreStrategic or Co-development PartnerSarasota Memorial Hospital is the principal investigator site for a clinical study evaluating LINFU for pancreatic cancer screening. Dr. Kenneth Meredith, Chief of GI Oncology at SMH's Brian D. Jellison Cancer Institute, serves as principal investigator. Five sisters with a family history of pancreatic cancer were among the first to enroll. The hospital produced and published a patient story video about LINFU and hosts a related podcast.
• GE (GE Healthcare)coreTechnology or IntegrationGE developed FDA-cleared ultrasound technology specifically for Adenocyte to support the LINFU procedure. Human clinical testing was conducted in 2022–2023 using this GE-developed ultrasound system. The partnership provided Adenocyte with the ultrasound hardware platform necessary for its proprietary waveform application.
• NYU Langone HealthmajorStrategic or Co-development PartnerDr. Gregory Haber, Professor of Medicine, Chief of Endoscopy, and Director of the Center for Advanced Therapeutics and Innovation at NYU Langone Health, has provided a formal expert endorsement of LINFU, describing its potential to fundamentally change GI practice. NYU Langone represents a key opinion leader and potential clinical adoption site.
• Lee HealthmajorStrategic or Co-development PartnerLee Health, a healthcare system in Florida, featured LINFU in a patient education video. Dr. Mark Bloomston, Surgical Oncologist at Lee Health, discussed how microbubble-enhanced ultrasound may help doctors collect pancreatic cellular material for analysis in patients at increased risk, indicating active clinical engagement with the technology.
• Rambam Health Care CampussupportingStrategic or Co-development PartnerDr. Iyad Khamaysi, Director of the Advanced Endoscopy Unit at Rambam Health Care Campus in Haifa, Israel, is involved in Adenocyte's clinical research. He is a Clinical Assistant Professor at the Technion's Faculty of Medicine and has research interests in pancreatic cancer research and medical device innovations.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Guardant Health: Liquid biopsy leader with the Shield blood test for colorectal cancer screening and the acquired Bluestar Genomics epigenomic pancreatic cancer program. Represents a broad incumbent in non-invasive cancer detection that competes for the same preventive screening dollars and clinical attention.
• Boston Scientific: Major medical device company with significant endoscopy and EUS franchise (acquired Apollo Endosurgery and others). A broad incumbent operating across the GI diagnostic and therapeutic device space that could expand into pancreatic cancer detection adjuncts.
• Exact Sciences: Commercialized Cologuard for colorectal cancer screening and is developing the Oncotype DX and pipeline of multi-cancer screening tests. A broad incumbent in non-invasive cancer screening with established screening infrastructure, channels, and reimbursement playbook.
• GRAIL: Multi-cancer early detection company with the Galleri test, which competes for population-level cancer screening budgets and clinical mindshare. A broad incumbent pursuing screening populations that overlap with Adenocyte's average-risk roadmap.
• Hologic: Women's health diagnostics leader with the ThinPrep Pap test franchise — the established precedent for cytological cancer screening that LINFU explicitly models itself on ("The Pap Smear for the Pancreas"). Broad incumbent in cytopathology-based cancer screening.
• Olympus Medical: Global leader in endoscopy systems, EUS endoscopes, and related GI devices. A broad incumbent that owns the installed-base endoscopy channel through which LINFU is delivered and could potentially bundle or compete with adjacent technologies.

Emerging players

• Natera: Molecular diagnostics company with the Signatera MRD test and expanding oncology screening/surveillance portfolio. Emerging player in cancer detection with overlapping customer base (oncologists, hospitals) and technology adjacency in liquid biopsy.
• Freenome: Multiomics blood-based early cancer detection company with its lead program in colorectal cancer screening and pipeline expansion into other cancers including pancreatic. An emerging player in the same liquid biopsy/cancer screening category.

Others

• GE HealthCare: Co-developed the FDA-cleared ultrasound hardware platform used for LINFU and is the technology/integration partner for the device. An enabling technology partner and broad incumbent in ultrasound imaging whose installed base and commercial reach materially influence LINFU's distribution economics.

Direct peers

• Immunovia: Swedish diagnostics company developing IMMray PanCan-d, a blood-based test for early pancreatic cancer detection in high-risk individuals. Directly competes with Adenocyte's LINFU for the same high-risk pancreatic cancer screening population, though via a different modality (blood vs. cytology).

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/adenocyte

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adenocyte